The inherent premise of immunotherapy for cancer dormancy

Cancer Research

Volumn 74, Issue 23, 2014, Pages 6745-6749

  Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT;

ADVANCED CANCER; BONE MARROW CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DORMANCY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CHEMOSENSITIVITY; CIRCULATING TUMOR CELL; DISTANT METASTASIS; DRUG CYTOTOXICITY; GENETIC CONSERVATION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIMARY TUMOR; REVIEW; TREATMENT RESPONSE; TUMOR IMMUNITY; ANIMAL; IMMUNOTHERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR RECURRENCE;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS;

EID: 84916918791     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2440     Document Type: Review

References (30)

1. Ibirogba SB, Spearman CW, Mall A, Shepherd E, Lotz Z, Tyler M, et al. Restoration of liver mass after partial hepatectomy -implications for living donor liver transplantation. S Afr J Surg 2005;43:70-2.
2. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-9.
3. Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787.
4. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009;69:836-44.
5. Gattelli A, Cirio MC, Quaglino A, Schere-Levy C, Martinez N, Binaghi M, et al.Progression of pregnancy-dependent mouse mammary tumors after long dormancy periods. Involvement of wnt pathway activation. Cancer Res 2004;64:5193-9.
6. Kmieciak M, Morales JK, Morales J, Bolesta E, Grimes M, Manjili MH. Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design. Cancer Immunol Immunother 2008;57:1391-8.
7. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011;17:320-9.
8. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003;82:199-206.
9. Jinno-Oue A, Shimizu N, Hamada N, Wada S, Tanaka A, Shinagawa M, et al.Irradiation with carbon ion beams induces apoptosis, autophagy, and cellular senescence in a human glioma-derived cell line. Int J Radiat Oncol Biol Phys 2010;76:229-41.
10. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
11. Li S, Kennedy M, Payne S, Kennedy K, Seewaldt VL, Pizzo SV, et al. Model of tumor dormancy/recurrence after short-term chemotherapy. PLoS ONE 2014;9:e98021.
12. Suzuki M, Mose ES, Montel V, Tarin D. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol 2006;169:673-81.
13. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009;15:677-83.
14. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-32.
15. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005;11:3678-85.
16. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al.The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013;15:807-17.
17. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al.Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012;13:688-95.
18. Xu W, Cao L, Chen L, Li J, Zhang XF, Qian HH, et al.Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 2011;17:3783-93.
19. Kauffman HM, McBride MA, Delmonico FL. First report of the united network for organ sharing transplant tumor registry: donors with a history of cancer. Transplantation 2000;70:1747-51.
20. Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation 2002;74:358-62.
21. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7.
22. Romero I, Garrido C, Algarra I, Collado A, Garrido F, Garcia-Lora AM. T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res 2014;74:1958-68.
23. Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, et al.Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol 1999;162:2842-9.
24. Mahnke YD, Schwendemann J, Beckhove P, Schirrmacher V. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 2005;115:325-36.
25. Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, et al.Vaccines targeting tumor blood vessel antigens promote CD8(+) T-cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 2012;188:1782-8.
26. Manjili MH. The adaptation model of immunity. Immunotherapy 2014;6:59-70.
27. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al.Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379-88.
28. Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T-cell-mediated anti-tumor immune responses. Eur J Immunol 2007;37:675-85.
29. Kmieciak M, Payne KK, Wang XY, Manjili MH. IFN-gamma ralpha is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. PLoS ONE 2013;8: e82544.
30. Saudemont A, Jouy N, Hetuin D, Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 2005;105: 2428-35.